Notably, compound 104 also exhibited nanomolar level inhibition against several other NSCLC-related oncogenes kinases, such as RET, EGFR, EGFR/T790M/L858R, DDR2, and ALK. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.